 Rajeev Vibhakar
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 40 | 2025 | 218 | 10.670 |
Why?
| | Cerebellar Neoplasms | 30 | 2025 | 179 | 8.650 |
Why?
| | Glioma | 19 | 2025 | 427 | 3.620 |
Why?
| | Gene Expression Regulation, Neoplastic | 30 | 2025 | 1431 | 3.610 |
Why?
| | Rhabdoid Tumor | 10 | 2025 | 98 | 3.480 |
Why?
| | Brain Neoplasms | 27 | 2025 | 1304 | 3.380 |
Why?
| | Radiation Tolerance | 8 | 2025 | 104 | 2.600 |
Why?
| | Proto-Oncogene Proteins c-myc | 8 | 2025 | 162 | 2.580 |
Why?
| | Cell Cycle Proteins | 8 | 2022 | 624 | 2.140 |
Why?
| | Cell Line, Tumor | 38 | 2025 | 3469 | 1.960 |
Why?
| | Cell Proliferation | 27 | 2025 | 2504 | 1.690 |
Why?
| | SMARCB1 Protein | 3 | 2025 | 29 | 1.540 |
Why?
| | Teratoma | 5 | 2022 | 118 | 1.480 |
Why?
| | Ependymoma | 11 | 2025 | 165 | 1.460 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2020 | 431 | 1.340 |
Why?
| | Nuclear Proteins | 10 | 2025 | 712 | 1.270 |
Why?
| | Pyrazoles | 7 | 2022 | 443 | 1.110 |
Why?
| | Apoptosis | 20 | 2025 | 2574 | 1.100 |
Why?
| | Proto-Oncogene Proteins | 4 | 2022 | 623 | 1.080 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 660 | 1.000 |
Why?
| | Biomarkers, Tumor | 9 | 2021 | 1251 | 0.970 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 51 | 0.930 |
Why?
| | Pyrimidines | 8 | 2019 | 477 | 0.920 |
Why?
| | Brain Stem Neoplasms | 4 | 2021 | 83 | 0.920 |
Why?
| | Sirtuin 2 | 1 | 2025 | 24 | 0.910 |
Why?
| | Cyclin-Dependent Kinase 6 | 4 | 2020 | 41 | 0.910 |
Why?
| | Molecular Targeted Therapy | 4 | 2021 | 419 | 0.910 |
Why?
| | Antineoplastic Agents | 10 | 2022 | 2166 | 0.870 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2016 | 43 | 0.860 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 830 | 0.850 |
Why?
| | Neoplastic Stem Cells | 5 | 2025 | 400 | 0.840 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 333 | 0.820 |
Why?
| | Xenograft Model Antitumor Assays | 10 | 2025 | 898 | 0.790 |
Why?
| | Genes, myc | 3 | 2020 | 48 | 0.790 |
Why?
| | MicroRNAs | 5 | 2020 | 689 | 0.790 |
Why?
| | Protein Biosynthesis | 1 | 2025 | 444 | 0.780 |
Why?
| | Pyrimidinones | 4 | 2020 | 114 | 0.770 |
Why?
| | Hedgehog Proteins | 7 | 2022 | 200 | 0.770 |
Why?
| | Cellular Senescence | 3 | 2019 | 205 | 0.730 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.710 |
Why?
| | Glioblastoma | 4 | 2025 | 347 | 0.710 |
Why?
| | Cell Cycle | 11 | 2017 | 597 | 0.710 |
Why?
| | Infratentorial Neoplasms | 4 | 2025 | 64 | 0.700 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.700 |
Why?
| | Mice | 26 | 2025 | 18048 | 0.690 |
Why?
| | Receptor, trkB | 1 | 2021 | 33 | 0.680 |
Why?
| | Anilides | 3 | 2019 | 70 | 0.680 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 63 | 0.670 |
Why?
| | Chromatin | 6 | 2025 | 529 | 0.670 |
Why?
| | Humans | 95 | 2025 | 141187 | 0.660 |
Why?
| | DNA Repair | 2 | 2024 | 234 | 0.650 |
Why?
| | Gene Expression Profiling | 15 | 2024 | 1764 | 0.640 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 38 | 0.640 |
Why?
| | Central Nervous System Neoplasms | 4 | 2019 | 169 | 0.630 |
Why?
| | Pteridines | 2 | 2016 | 21 | 0.590 |
Why?
| | Deoxycytidine | 1 | 2020 | 192 | 0.590 |
Why?
| | Cerebellum | 5 | 2022 | 218 | 0.580 |
Why?
| | Tumor Cells, Cultured | 9 | 2025 | 959 | 0.570 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 501 | 0.570 |
Why?
| | Oligonucleotide Array Sequence Analysis | 10 | 2016 | 761 | 0.570 |
Why?
| | Transcription Factors | 6 | 2023 | 1703 | 0.550 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 528 | 0.550 |
Why?
| | Histones | 4 | 2020 | 639 | 0.540 |
Why?
| | Animals | 27 | 2025 | 37657 | 0.520 |
Why?
| | Blotting, Western | 8 | 2019 | 1234 | 0.510 |
Why?
| | Vinblastine | 1 | 2016 | 71 | 0.510 |
Why?
| | RNA, Small Interfering | 4 | 2022 | 626 | 0.510 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.510 |
Why?
| | Mutation | 9 | 2025 | 4013 | 0.500 |
Why?
| | Radiation, Ionizing | 3 | 2022 | 80 | 0.500 |
Why?
| | Bilirubin | 1 | 2016 | 90 | 0.500 |
Why?
| | Vincristine | 1 | 2016 | 131 | 0.490 |
Why?
| | Cell Survival | 8 | 2019 | 1129 | 0.480 |
Why?
| | CRISPR-Cas Systems | 3 | 2025 | 150 | 0.480 |
Why?
| | Transcriptome | 6 | 2025 | 1003 | 0.460 |
Why?
| | Enzyme Inhibitors | 6 | 2020 | 854 | 0.460 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2016 | 135 | 0.460 |
Why?
| | Child | 32 | 2025 | 22308 | 0.460 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2012 | 66 | 0.450 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2025 | 222 | 0.440 |
Why?
| | Single-Cell Analysis | 5 | 2025 | 338 | 0.430 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2023 | 210 | 0.420 |
Why?
| | Cell Differentiation | 7 | 2025 | 2003 | 0.420 |
Why?
| | RNA, Messenger | 7 | 2014 | 2828 | 0.410 |
Why?
| | Repressor Proteins | 3 | 2022 | 425 | 0.370 |
Why?
| | Child, Preschool | 19 | 2025 | 11457 | 0.350 |
Why?
| | Piperazines | 3 | 2022 | 354 | 0.340 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 692 | 0.340 |
Why?
| | Azepines | 3 | 2019 | 97 | 0.340 |
Why?
| | Transcription, Genetic | 3 | 2025 | 1487 | 0.330 |
Why?
| | Prognosis | 9 | 2020 | 4073 | 0.330 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 987 | 0.330 |
Why?
| | Neoplasms, Neuroepithelial | 2 | 2020 | 15 | 0.320 |
Why?
| | Intracellular Space | 1 | 2010 | 68 | 0.320 |
Why?
| | NF-kappa B | 5 | 2025 | 692 | 0.320 |
Why?
| | Genes, Tumor Suppressor | 2 | 2007 | 82 | 0.320 |
Why?
| | Neoplasm Proteins | 2 | 2012 | 432 | 0.310 |
Why?
| | Reactive Oxygen Species | 2 | 2022 | 630 | 0.300 |
Why?
| | Cisplatin | 3 | 2016 | 327 | 0.300 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2014 | 346 | 0.300 |
Why?
| | Drug Screening Assays, Antitumor | 4 | 2021 | 193 | 0.290 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 75 | 0.290 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 914 | 0.280 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1787 | 0.280 |
Why?
| | Quinazolines | 2 | 2022 | 250 | 0.280 |
Why?
| | Signal Transduction | 10 | 2025 | 5144 | 0.270 |
Why?
| | Mice, Nude | 3 | 2020 | 691 | 0.260 |
Why?
| | B7 Antigens | 2 | 2020 | 14 | 0.260 |
Why?
| | Aurora Kinases | 3 | 2012 | 28 | 0.260 |
Why?
| | DNA-Binding Proteins | 3 | 2017 | 1478 | 0.260 |
Why?
| | Aurora Kinase A | 3 | 2012 | 55 | 0.260 |
Why?
| | Combined Modality Therapy | 6 | 2019 | 1243 | 0.250 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2025 | 546 | 0.250 |
Why?
| | Female | 28 | 2025 | 75515 | 0.250 |
Why?
| | Phagocytosis | 2 | 2025 | 388 | 0.240 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2020 | 53 | 0.240 |
Why?
| | AC133 Antigen | 1 | 2025 | 21 | 0.240 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 51 | 0.240 |
Why?
| | Autophagy | 2 | 2019 | 287 | 0.240 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | Epigenomics | 3 | 2020 | 114 | 0.230 |
Why?
| | Triazoles | 2 | 2019 | 157 | 0.230 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 72 | 0.230 |
Why?
| | RNA Polymerase II | 2 | 2025 | 339 | 0.230 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 388 | 0.230 |
Why?
| | SOXB1 Transcription Factors | 1 | 2025 | 63 | 0.230 |
Why?
| | Gene Fusion | 1 | 2025 | 26 | 0.230 |
Why?
| | Ganglioglioma | 1 | 2025 | 35 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2022 | 1073 | 0.230 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2019 | 139 | 0.230 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 25 | 0.220 |
Why?
| | Phenanthrenes | 1 | 2024 | 12 | 0.220 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 101 | 0.220 |
Why?
| | Diterpenes | 1 | 2024 | 27 | 0.220 |
Why?
| | Epoxy Compounds | 1 | 2024 | 31 | 0.220 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2025 | 200 | 0.210 |
Why?
| | Gene Rearrangement | 1 | 2025 | 151 | 0.210 |
Why?
| | Abnormalities, Multiple | 1 | 2005 | 197 | 0.210 |
Why?
| | Survival Rate | 5 | 2020 | 1970 | 0.200 |
Why?
| | Metencephalon | 1 | 2022 | 1 | 0.200 |
Why?
| | Cell Lineage | 2 | 2022 | 350 | 0.190 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 423 | 0.190 |
Why?
| | Disease-Free Survival | 3 | 2016 | 715 | 0.190 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.190 |
Why?
| | Stress, Physiological | 1 | 2025 | 454 | 0.180 |
Why?
| | von Willebrand Diseases | 1 | 2022 | 28 | 0.180 |
Why?
| | DNA Copy Number Variations | 4 | 2021 | 176 | 0.180 |
Why?
| | Genome, Human | 3 | 2014 | 420 | 0.180 |
Why?
| | Spheroids, Cellular | 2 | 2012 | 77 | 0.180 |
Why?
| | von Willebrand Factor | 1 | 2022 | 84 | 0.180 |
Why?
| | Radiation | 1 | 2021 | 25 | 0.180 |
Why?
| | Pyridines | 3 | 2019 | 510 | 0.170 |
Why?
| | Neural Stem Cells | 2 | 2012 | 161 | 0.170 |
Why?
| | Mice, Transgenic | 3 | 2021 | 2180 | 0.170 |
Why?
| | RNA, Long Noncoding | 2 | 2021 | 173 | 0.170 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 33 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2021 | 309 | 0.160 |
Why?
| | Ephrin-B2 | 1 | 2020 | 45 | 0.160 |
Why?
| | Macrophages | 2 | 2025 | 1561 | 0.160 |
Why?
| | Antigens, Surface | 2 | 1997 | 156 | 0.160 |
Why?
| | Colony-Forming Units Assay | 2 | 2012 | 96 | 0.160 |
Why?
| | Craniospinal Irradiation | 1 | 2019 | 5 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 76 | 0.160 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2019 | 204 | 0.160 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.160 |
Why?
| | Adolescent | 13 | 2025 | 22007 | 0.160 |
Why?
| | RNA, Small Nuclear | 1 | 2019 | 37 | 0.160 |
Why?
| | Karyopherins | 1 | 2019 | 20 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2064 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 908 | 0.150 |
Why?
| | Benzamides | 3 | 2019 | 216 | 0.150 |
Why?
| | Proteins | 3 | 2021 | 1010 | 0.150 |
Why?
| | Male | 21 | 2025 | 69783 | 0.150 |
Why?
| | Cell Self Renewal | 1 | 2019 | 54 | 0.150 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2021 | 874 | 0.150 |
Why?
| | Phenotype | 3 | 2024 | 3166 | 0.150 |
Why?
| | Base Sequence | 4 | 2012 | 2180 | 0.140 |
Why?
| | Infant | 12 | 2021 | 9818 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1448 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 232 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 209 | 0.140 |
Why?
| | Neoplasms | 2 | 2025 | 2741 | 0.140 |
Why?
| | Genes, p16 | 1 | 2017 | 15 | 0.130 |
Why?
| | Sulfonamides | 2 | 2022 | 520 | 0.130 |
Why?
| | E2F Transcription Factors | 1 | 2017 | 62 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 110 | 0.130 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 16 | 0.130 |
Why?
| | Cohort Studies | 6 | 2021 | 5799 | 0.130 |
Why?
| | DNA Methylation | 4 | 2021 | 645 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 126 | 0.130 |
Why?
| | DNA Damage | 2 | 2017 | 427 | 0.130 |
Why?
| | Cell Division | 2 | 2010 | 798 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 53 | 0.130 |
Why?
| | Phthalazines | 1 | 2017 | 51 | 0.130 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.130 |
Why?
| | Stem Cells | 1 | 2021 | 602 | 0.130 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2017 | 160 | 0.130 |
Why?
| | Up-Regulation | 2 | 2016 | 859 | 0.130 |
Why?
| | Microarray Analysis | 2 | 2017 | 116 | 0.120 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 81 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2017 | 329 | 0.120 |
Why?
| | Urea | 1 | 2016 | 81 | 0.120 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 509 | 0.120 |
Why?
| | Thiophenes | 1 | 2016 | 122 | 0.120 |
Why?
| | Lysine | 2 | 2020 | 292 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2025 | 310 | 0.120 |
Why?
| | Survival Analysis | 2 | 2010 | 1319 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 444 | 0.120 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2016 | 192 | 0.120 |
Why?
| | Mitosis | 1 | 2016 | 196 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 325 | 0.110 |
Why?
| | Genomics | 3 | 2017 | 814 | 0.110 |
Why?
| | HeLa Cells | 1 | 2016 | 640 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 297 | 0.110 |
Why?
| | Promoter Regions, Genetic | 3 | 2017 | 1242 | 0.110 |
Why?
| | Lymphocyte Activation | 2 | 2002 | 1150 | 0.110 |
Why?
| | Brain | 2 | 2020 | 2858 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 204 | 0.100 |
Why?
| | Retrospective Studies | 6 | 2025 | 16273 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.100 |
Why?
| | Indoles | 1 | 2017 | 429 | 0.100 |
Why?
| | Flow Cytometry | 2 | 2019 | 1197 | 0.100 |
Why?
| | Phosphorylation | 4 | 2020 | 1768 | 0.100 |
Why?
| | Cathepsin B | 1 | 2012 | 14 | 0.100 |
Why?
| | Cell Movement | 2 | 2020 | 990 | 0.100 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.100 |
Why?
| | Argonaute Proteins | 1 | 2012 | 27 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2014 | 136 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 434 | 0.100 |
Why?
| | Acetylcysteine | 1 | 2013 | 142 | 0.100 |
Why?
| | Genomic Structural Variation | 1 | 2012 | 12 | 0.100 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 144 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 209 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 150 | 0.090 |
Why?
| | Astrocytoma | 2 | 2025 | 131 | 0.090 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 149 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2599 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2012 | 740 | 0.090 |
Why?
| | Colorado | 1 | 2022 | 4610 | 0.090 |
Why?
| | Carcinogenesis | 2 | 2025 | 215 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 146 | 0.090 |
Why?
| | Quality of Life | 2 | 2023 | 2999 | 0.090 |
Why?
| | Telomerase | 1 | 2013 | 247 | 0.090 |
Why?
| | Acetylation | 1 | 2011 | 245 | 0.090 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2012 | 134 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 469 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2015 | 792 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 262 | 0.080 |
Why?
| | Adenosine | 1 | 2012 | 244 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2017 | 646 | 0.080 |
Why?
| | Tyrosine | 2 | 2023 | 228 | 0.080 |
Why?
| | Aging | 1 | 2020 | 1892 | 0.080 |
Why?
| | Ki-67 Antigen | 2 | 2022 | 111 | 0.080 |
Why?
| | Hydroxamic Acids | 2 | 2007 | 92 | 0.080 |
Why?
| | Radiosurgery | 1 | 2014 | 392 | 0.080 |
Why?
| | Superoxides | 1 | 2010 | 217 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 316 | 0.080 |
Why?
| | Gene Silencing | 2 | 2007 | 196 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4404 | 0.080 |
Why?
| | Histone Demethylases | 2 | 2022 | 31 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 1997 | 2002 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 405 | 0.070 |
Why?
| | Cluster Analysis | 3 | 2017 | 521 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 641 | 0.070 |
Why?
| | Syndrome | 2 | 2005 | 378 | 0.070 |
Why?
| | Nerve Tissue Proteins | 2 | 2012 | 601 | 0.060 |
Why?
| | Scrotum | 1 | 2006 | 26 | 0.060 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2005 | 23 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 18 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 41 | 0.060 |
Why?
| | Transplantation Chimera | 1 | 2005 | 59 | 0.060 |
Why?
| | Young Adult | 5 | 2021 | 13673 | 0.060 |
Why?
| | Anemia, Aplastic | 1 | 2005 | 42 | 0.060 |
Why?
| | Drug Synergism | 2 | 2017 | 375 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 45 | 0.060 |
Why?
| | Computer Simulation | 2 | 2021 | 1015 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2929 | 0.060 |
Why?
| | RNA | 1 | 2012 | 930 | 0.060 |
Why?
| | Neuroblastoma | 1 | 2006 | 163 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2025 | 37 | 0.060 |
Why?
| | Testicular Neoplasms | 1 | 2006 | 115 | 0.060 |
Why?
| | Paraffin Embedding | 1 | 2025 | 33 | 0.060 |
Why?
| | Neutropenia | 1 | 2005 | 157 | 0.060 |
Why?
| | Formaldehyde | 1 | 2025 | 67 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3588 | 0.050 |
Why?
| | Transplantation Conditioning | 1 | 2005 | 184 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2363 | 0.050 |
Why?
| | Prodrugs | 1 | 2024 | 46 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 105 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 11120 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 254 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 206 | 0.050 |
Why?
| | Graft Survival | 1 | 2005 | 499 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 156 | 0.050 |
Why?
| | Core Binding Factor alpha Subunits | 1 | 2022 | 2 | 0.050 |
Why?
| | Otx Transcription Factors | 1 | 2022 | 13 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 168 | 0.050 |
Why?
| | Weibel-Palade Bodies | 1 | 2022 | 6 | 0.050 |
Why?
| | fas Receptor | 1 | 2002 | 97 | 0.050 |
Why?
| | Lymphoproliferative Disorders | 1 | 2002 | 60 | 0.050 |
Why?
| | T-Box Domain Proteins | 1 | 2022 | 100 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 108 | 0.040 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 58 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 236 | 0.040 |
Why?
| | Antigens, CD | 3 | 2002 | 539 | 0.040 |
Why?
| | Muscle Proteins | 1 | 2022 | 240 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 464 | 0.040 |
Why?
| | Ifosfamide | 1 | 2020 | 38 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 238 | 0.040 |
Why?
| | Transcription Factor HES-1 | 1 | 2019 | 5 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5200 | 0.040 |
Why?
| | Smoothened Receptor | 1 | 2019 | 6 | 0.040 |
Why?
| | MyoD Protein | 1 | 2019 | 33 | 0.040 |
Why?
| | Gain of Function Mutation | 1 | 2019 | 34 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2020 | 256 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 10438 | 0.040 |
Why?
| | RNA Splice Sites | 1 | 2019 | 50 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 1997 | 194 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 104 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 313 | 0.040 |
Why?
| | Adult | 5 | 2021 | 39177 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 1997 | 257 | 0.040 |
Why?
| | Autoimmune Diseases | 1 | 2002 | 464 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 600 | 0.030 |
Why?
| | RNA Splicing | 1 | 2019 | 270 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 720 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 92 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 25 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 34 | 0.030 |
Why?
| | Consensus | 1 | 2021 | 704 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 232 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 943 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 511 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1997 | 156 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1997 | 274 | 0.030 |
Why?
| | Jurkat Cells | 1 | 1997 | 138 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 129 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 112 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 386 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 324 | 0.030 |
Why?
| | Radiotherapy | 1 | 2017 | 208 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 1000 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 378 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 368 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 91 | 0.030 |
Why?
| | Canada | 1 | 2016 | 428 | 0.030 |
Why?
| | Zinc Finger Protein Gli2 | 1 | 2014 | 4 | 0.030 |
Why?
| | Cytogenetics | 1 | 2014 | 10 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 823 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 21 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2014 | 52 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 1 | 1997 | 411 | 0.030 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2014 | 60 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2015 | 151 | 0.030 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2014 | 67 | 0.030 |
Why?
| | Gene Expression | 2 | 2010 | 1491 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 75 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 567 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1737 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 196 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 398 | 0.020 |
Why?
| | Middle Aged | 3 | 2021 | 34434 | 0.020 |
Why?
| | Gene Duplication | 1 | 2012 | 65 | 0.020 |
Why?
| | Methylation | 1 | 2012 | 230 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 579 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 519 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3709 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 1997 | 858 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 2012 | 109 | 0.020 |
Why?
| | Glutathione | 1 | 2013 | 356 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2890 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1261 | 0.020 |
Why?
| | Genome | 1 | 2012 | 302 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5887 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3292 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 497 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1859 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2070 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2793 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2098 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5929 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3348 | 0.010 |
Why?
| | Azacitidine | 1 | 2006 | 150 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2132 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3490 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2002 | 66 | 0.010 |
Why?
| | Lectins, C-Type | 1 | 2002 | 63 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 97 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2746 | 0.010 |
Why?
| | Cytoplasm | 1 | 2002 | 273 | 0.010 |
Why?
| | Interleukin-4 | 1 | 2002 | 215 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2002 | 453 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 415 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2011 | 6275 | 0.010 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2002 | 393 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2002 | 792 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 76 | 0.010 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 1997 | 28 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1997 | 156 | 0.010 |
Why?
| | Interleukin-7 | 1 | 1997 | 62 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1997 | 92 | 0.010 |
Why?
| | Genes | 1 | 1997 | 229 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1997 | 391 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1187 | 0.010 |
Why?
| | Bone Marrow | 1 | 1997 | 302 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1997 | 1274 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2158 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1997 | 4208 | 0.000 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|